

Publikationen KKH

Publikationen Neuroonkologie

Wiemann G, Pertz M, Kowalski T, Seidel S, **Schlegel U**, Thoma P. Complete response to therapy: why do primary central nervous system lymphoma patients not return to work? *J Neurooncol.* 2020;doi: 10.1007/s11060-020-03587-5. Online ahead of print.

Waldera-Lupa DM, Poschmann G, Kirchgaessler N, Etemad-Parishanzadeh O, Baberg F, Brocksieper M, Seidel S, Kowalski T, Brunn A, Haghikia A, Gold R, Stefanski A, Deckert M, **Schlegel U**, Stühler K. A multiplex assay for the stratification of patients with primary Central Nervous System Lymphoma using targeted mass spectrometry. *Cancers (Basel)* 2020;12: EE1732.doi:

Pertz M, Popkirov S, **Schlegel U**, Thoma P. Research on cognitive and sociocognitive functions in patients with brain tumors: a bibliometric analysis and visualization of the scientific landscape. *Neurol Sci* 2020;Epub Feb 2020

Pertz M, Okoniewski A, **Schlegel U**, Thoma P. Impairment of sociocognitive functions in patients with brain tumours. *Neuroscience and Biobehavioral Reviews* 2020;108: 370–392

Seidel S, Korfel A, Kowalski T, Margold M, Ismail F, **Schroers R**, **Baraniskin A**, Pels H, Martus P, **Schlegel U**. HDMTX-based induction therapy followed by consolidation with conventional systemic chemotherapy and intraventricular therapy (modified Bonn protocol) in primary CNS lymphoma: a monocentric retrospective analysis. *Neurol. Res. Pract.* 2019;1:17

Seidel S, **Schlegel U**. Have treatment protocols for primary CNS lymphoma advanced in the past 10 years. *Expert Rev Anticancer Ther.* 2019;19: 909 - 915

Weller J, Tzaridis T, Mack F, Steinbach JP, **Schlegel U**, Hau P, Krex D, Grauer O, Goldbrunner R, Bähr O, Uhl M, Seidel C, Tabatabai G, Brehmer S, Bullinger L, Galldiks N, Schaub C, Kebir S, Stummer W, Simon M, Fimmers R, Coch C, Glas M, Herrlinger U, Schäfer N. Health-related quality of life and neurocognitive functioning with lomustine-temozolomide versus temozolomide in patients with newly diagnosed, MGMT-methylated glioblastoma (CeTeG/NOA-09): a randomised, multicentre, open-label, phase 3 trial. *Lancet Oncol.* 2019;20: 1444 - 1453

Kebir S, Schaub C, Junold N, Hattingen E, Schäfer N, Steinbach JP, Weyerbrock A, Hau P, Goldbrunner R, Galldiks N, Weller J, Mack F, Tzaridis T, Bähr O, Seidel C, **Schlegel U**, Schmidt-Graf F, Rohde V, Borchers C, Tabatabai G, Hänel M, Sabel M, Gerlach R, Krex D, Belka C, Vatter H, Proescholdt M, Glas M, Herrlinger U. Baseline T1 hyperintense and diffusion-restricted lesions are not linked to prolonged survival in bevacizumab-treated glioblastoma patients of the GLARIUS trial. *J Neurooncol.* 2019;144: 501 - 509

Binder H, Willscher E, Loeffler-Wirth H, Hopp L, Jones DTW, Pfister SM, Kreuz M, Gramatzki D, Fortenbacher E, Hentschel B, Tatagiba M, Herrlinger U, Vatter H, Matschke J, Westpfahl M, Krex D, Schackert G, Tonn JC, **Schlegel U**, Steiger HJ, Wick W, Weber RG, Weller M, Loeffler M. DNA methylation, transcriptome and genetic copy number signatures of diffuse cerebral WHO grade II/III gliomas resolve cancer heterogeneity and development. *Acta Neuropathol Commun.* 2019;7: 59

Herrlinger U, Tzaridis T, Mack F, Steinbach JP, **Schlegel U**, Sabel M, Hau P, Kortmann RD, Krex D, Grauer O, Goldbrunner R, Schnell O, Bähr O, Uhl M, Seidel C, Tabatabai G, Kowalski T, Ringel F, Schmidt-Graf F, Suchorska B, Brehmer S, Weyenbrock A, Renovanz M, Bullinger L, Galldiks N, Vajkoczny P, Misch M, Vatter H, Stuplich M, Schäfer N, Kebir S, Weller J, Schaub C, Stummer W, Tonn JC, Simon M, Keil VC, Nelles M, Urbach H, Coenen M, Wick W, Weller

M, Fimmers R, Schmid M, Hattingen E, Pietsch T, Coch C, Glas M, Neurooncology Working Group of the German Cancer Society. Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promotor (CeTeG/NOA 09): a randomized, open-label, phase 3 trial. *Lancet* 2019;393: 678 – 688

Abteilung für Hämatologie und Onkologie

Al-Batran SE, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S, Kopp HG, Mayer F, Haag GM, Luley K, Lindig U, **Schmiegel W**, **Pohl M**, Stoehlmacher J, Folprecht G, Probst S, Prasnikař N, Fischbach W, Mahlberg R, Trojan J, Koenigsmann M, Martens UM, Thuss-Patience P, Egger M, Block A, Heinemann V, Illerhaus G, Moehler M, Schenk M, Kullmann F, Behringer DM, Heike M, Pink D, Teschendorf C, Löhr C, Bernhard H, Schuch G, Rethwisch V, von Weikersthal LF, Hartmann JT, Kneba M, Daum S, Schulmann K, Weniger J, Belle S, Gaiser T, Oduncu FS, Güntner M, Hozaeel W, Reichart A, Jäger E, Kraus T, Mönig S, Bechstein WO, Schuler M, Schmalenberg H, Hofheinz RD; FLOT4-AIO Investigators. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial.

Lancet. 2019 May 11;393(10184):1948-1957. doi: 10.1016/S0140-6736(18)32557-1.

Impact Factor: 60,392

Baraniskin A, Buchberger B, Pox C, Graeven U, Holch JW, **Schmiegel W**, Heinemann V. Efficacy of bevacizumab in first-line treatment of metastatic colorectal cancer: A systematic review and meta-analysis.

Eur J Cancer. 2019 Jan;106:37-44. doi: 10.1016/j.ejca.2018.10.009.

Impact Factor: 7,275

Blanco Belder A, Aach M, **Schmiegel W**, Schildhauer TA, Meindl R, Brechmann T. Similar Adenoma Detection Rates in Colonoscopic Procedures of Patients with Spinal Cord Injury Compared to Controls.

Dig Dis Sci. 2020 Apr;65(4):1197-1205. doi: 10.1007/s10620-019-05814-0.

Impact Factor: 2,751

Brechmann T, Günther K, Neid M, Tannapfel A, **Schmiegel W**.

Phenotype of histologically suspected drug-induced colitis; results of a comparative, retrospective cohort study.

Scand J Gastroenterol. 2019 Jul;54(7):855-862. doi: 10.1080/00365521.2019.1630674.

Impact Factor: 2,130

Brechmann T, Günther K, Neid M, **Schmiegel W**, Tannapfel A.

Triggers of histologically suspected drug-induced colitis.

World J Gastroenterol. 2019 Feb 28;25(8):967-979. doi: 10.3748/wjg.v25.i8.967.

Impact Factor: 3,665

Dominguez-Valentin M, Sampson JR, Seppälä TT, Ten Broeke SW, Plazzer JP, Nakken S, Engel C, Aretz S, Jenkins MA, Sunde L, Bernstein I, Capella G, Balaguer F, Thomas H, Evans DG, Burn J, Greenblatt M, Hovig E, de Vos Tot Nederveen Cappel WH, Sijmons RH, Bertario L, Tibiletti MG, Cavestro GM, Lindblom A, Della Valle A, Lopez-Köstner F, Gluck N, Katz LH, Heinemann K, Vaccaro CA, Büttner R, Görgens H, Holinski-Feder E, Morak M, Holzapfel S, Hüneburg R, Knebel Doeberitz MV, Loeffler M, Rahner N, Schackert HK, Steinke-Lange V, **Schmiegel W**, **Vangala D**, Pylvänäinen K, Renkonen-Sinisalo L, Hopper JL, Win AK, Haile RW, Lindor NM, Gallinger S, Le Marchand L, Newcomb PA, Figueiredo JC, Thibodeau SN, Wadt K, Therkildsen C, Okkels H, Ketabi Z, Moreira L, Sánchez A, Serra-Burriel M, Pineda M, Navarro M, Blanco I, Green K, Lalloo F, Crosbie EJ, Hill J, Denton OG,

Frayling IM, Rødland EA, Vasen H, Mints M, Neffa F, Esperon P, Alvarez K, Kariv R, Rosner G, Pinero TA, Gonzalez ML, Kalfayan P, Tjandra D, Winship IM, Macrae F, Möslein G, Mecklin JP, Nielsen M, Møller P.

Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database.

Genet Med. 2020 Jan;22(1):15-25. doi: 10.1038/s41436-019-0596-9.

Impact Factor: 8,904

Fokas E, Allgäuer M, Polat B, Klautke G, Grabenbauer GG, Fietkau R, Kuhnt T, Staib L, Brunner T, Grosu AL, **Schmiegel** W, Jacobasch L, Weitz J, Folprecht G, Schlenska-Lange A, Flentje M, Germer CT, Grützmann R, Schwarzbach M, Paolucci V, Bechstein WO, Friede T, Ghadimi M, Hofheinz RD, Rödel C; German Rectal Cancer Study Group.

Randomized Phase II Trial of Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: CAO/ARO/AIO-12.

J Clin Oncol. 2019 Dec 1;37(34):3212-3222. doi: 10.1200/JCO.19.00308.

Impact Factor: 32,956

Gottlieb A, **Canbay** A.

Why Bile Acids Are So Important in Non-Alcoholic Fatty Liver Disease (NAFLD) Progression.

Cells. 2019 Oct 30;8(11):1358. doi: 10.3390/cells8111358.

Impact Factor: 4,366

Hüneburg R, Aretz S, Büttner R, Daum S, Engel C, Fechner G, Habermann JK, Heling D, Hoffmann K, Holinski-Feder E, Kloor M, von Knebel-Döberitz M, Loeffler M, Möslein G, Perne C, Redler S, Rieß O, **Schmiegel** W, Seufferlein T, Siebers-Renelt U, Steinke-Lange V, Tecklenburg J, **Vangala** D, Vilz T, Weitz J, Wiedenmann B, Strassburg CP, Nattermann J. [Current recommendations for surveillance, risk reduction and therapy in Lynch syndrome patients].

Z Gastroenterol. 2019 Nov;57(11):1309-1320. doi: 10.1055/a-1008-9827.

Impact Factor: 1,338

Hüttmann A, Rekowski J, Müller SP, Hertenstein B, Franzius C, Mesters R, Weckesser M, Kroschinsky F, Kotzerke J, Ganser A, Bengel FM, La Rosée P, Freesmeyer M, Höffkes HG, Hertel A, Behringer D, Prange-Krex G, Griesshammer M, Holzinger J, Wilop S, Krohn T, Raghavachar A, Maschmeyer G, Brink I, **Schroers** R, Gaska T, Bernhard H, Giagounidis A, Schütte J, Dienst A, Hautzel H, Naumann R, Klein A, Hahn D, Pöpperl G, Grube M, Marienhagen J, Schwarzer A, Kurch L, Höhler T, Steiniger H, Nückel H, Südhoff T, Römer W, Brinkmann M, Ose C, Alashkar F, Schmitz C, Dürig J, Hoelzer D, Jöckel KH, Klapper W, Dührsen U.

Six versus eight doses of rituximab in patients with aggressive B cell lymphoma receiving six cycles of CHOP: results from the "Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas" (PETAL) trial.

Ann Hematol. 2019 Apr;98(4):897-907. doi: 10.1007/s00277-018-3578-0.

Impact Factor: 2,904

Ladigan S, Mika T, Figge A, May AM, **Schmiegel** W, **Schroers** R, **Baraniskin** A.

Acute myeloid leukemia with central diabetes insipidus.

Blood Cells Mol Dis. 2019 May;76:45-52. doi: 10.1016/j.bcmd.2019.01.005.

Impact Factor: 2,460

Mika T, Ladigan S, Schork K, Turewicz M, Eisenacher M, **Schmiegel** W, **Schroers** R, **Baraniskin** A.

Monocytes-neutrophils-ratio as predictive marker for failure of first induction therapy in AML.

Blood Cells Mol Dis. 2019 Jul;77:103-108. doi: 10.1016/j.bcmd.2019.04.008.

Impact Factor: 2,460

Mika T, Strate K, Ladigan S, Aigner C, Schlegel U, Tischoff I, Tischer-Zimmermann S, Eiz-Vesper B, Maecker-Kolhoff B, **Schroers R**.

Refractory Epstein-Barr Virus (EBV)-Related Post-transplant Lymphoproliferative Disease: Cure by Combined Brentuximab Vedotin and Allogeneic EBV-Specific T-Lymphocytes. *Front Med (Lausanne)*. 2019 Dec 18;6:295. doi: 10.3389/fmed.2019.00295.

Impact Factor: 3,9

Mika T, **Baraniskin A**, Ladigan S, Wulf G, Dierks S, Haase D, Schork K, Turewicz M, Eisenacher M, **Schmiegel W**, **Schroers R**, Klein-Scory S.

Digital droplet PCR-based chimerism analysis for monitoring of hematopoietic engraftment after allogeneic stem cell transplantation.

Int J Lab Hematol. 2019 Oct;41(5):615-621. doi: 10.1111/ijlh.13073.

Impact Factor: 2,141

Moehler M, Al-Batran SE, Andus T, Arends J, Arnold D, Baretton G, Bornschein J, Budach W, Daum S, Dietrich C, Ebert M, Fischbach W, Flentje M, Gockel I, Grenacher L, Haier J, Höcht S, Jakobs R, Jenssen C, Kade B, Kanzler S, Langhorst J, Link H, Lordick F, Lorenz D, Lorenzen S, Lutz M, Messmann H, Meyer HJ, Mönig S, Ott K, Quante M, Röcken C, Schlattmann P, **Schmiegel WH**, Schreyer A, Tannapfel A, Thuss-Patience P, Weimann A, Unverzagt S.

S3-Leitlinie Magenkarzinom – Diagnostik und Therapie der Adenokarzinome des Magens und des ösophagogastralen Übergangs – Langversion 2.0 – August 2019. AWMF-Registernummer: 032/009OL.

Z Gastroenterol. 2019 Dec;57(12):1517-1632. doi: 10.1055/a-1018-2516.

Impact Factor: 1,338

Mölleken C, Ahrens M, Schlosser A, Dietz J, Eisenacher M, Meyer HE, **Schmiegel W**, Holmskov U, Sarrazin C, Sorensen GL, Sitek B, Bracht T.

Direct-acting antivirals-based therapy decreases hepatic fibrosis serum biomarker microfibrillar-associated protein 4 in hepatitis C patients.

Clin Mol Hepatol. 2019 Mar;25(1):42-51. doi: 10.3350/cmh.2018.0029.

Impact Factor: 7,275

Ortmann O, Torode J, **Schmiegel W**, Thomssen C, Hakama M, Basu P, Ringborg U, Helbig U; participants of the ERTM.

Knowledge transfer as a tool towards improvement of cancer care in low- and middle-income countries. 6th European Roundtable Meeting (ERTM), June 14th, 2019, Berlin, Germany.

J Cancer Res Clin Oncol. 2020 Jul;146(7):1813-1818. doi: 10.1007/s00432-020-03209-7.

Impact Factor: 3,656

Rücker FG, Agrawal M, Corbacioglu A, Weber D, Kapp-Schwoerer S, Gaidzik VI, Jahn N, Schroeder T, Wattad M, Lübbert M, Koller E, Kindler T, Götze K, Ringhoffer M, Westermann J, Fiedler W, Horst HA, Greil R, **Schroers R**, Mayer K, Heinicke T, Krauter J, Schlenk RF, Thol F, Heuser M, Ganser A, Bullinger L, Paschka P, Döhner H, Döhner K.

Measurable residual disease monitoring in acute myeloid leukemia with t(8;21)(q22;q22.1): results from the AML Study Group.

Blood. 2019 Nov 7;134(19):1608-1618. doi: 10.1182/blood.2019001425.

Impact Factor: 17,543

Schlenk RF, Weber D, Fiedler W, Salih HR, Wulf G, Salwender H, Schroeder T, Kindler T, Lübbert M, Wolf D, Westermann J, Kraemer D, Götze KS, Horst HA, Krauter J, Girschikofsky M, Ringhoffer M, Südhoff T, Held G, Derigs HG, **Schroers R**, Greil R, Gießhammer M, Lange E, Burchardt A, Martens U, Hertenstein B, Marretta L, Heuser M, Thol F, Gaidzik VI, Herr W, Krzykalla J, Benner A, Döhner K, Ganser A, Paschka P, Döhner H; German-Austrian AML Study Group.

Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with *FLT3*-ITD. *Blood*. 2019 Feb 21;133(8):840-851. doi: 10.1182/blood-2018-08-869453. Impact Factor: 17,543

Seppälä TT, Ahadova A, Dominguez-Valentin M, Macrae F, Evans DG, Therkildsen C, Sampson J, Scott R, Burn J, Möslein G, Bernstein I, Holinski-Feder E, Pylvänäinen K, Renkonen-Sinisalo L, Lepistö A, Lautrup CK, Lindblom A, Plazzer JP, Winship I, Tjandra D, Katz LH, Aretz S, Hüneburg R, Holzapfel S, Heinimann K, Valle AD, Neffa F, Gluck N, de Vos Tot Nederveen Cappel WH, Vasen H, Morak M, Steinke-Lange V, Engel C, Rahner N, **Schmieg** W, **Vangala** D, Thomas H, Green K, Laloo F, Crosbie EJ, Hill J, Capella G, Pineda M, Navarro M, Blanco I, Ten Broeke S, Nielsen M, Ljungmann K, Nakken S, Lindor N, Frayling I, Hovig E, Sunde L, Kloor M, Mecklin JP, Kalager M, Møller P. Lack of association between screening interval and cancer stage in Lynch syndrome may be accounted for by over-diagnosis; a prospective Lynch syndrome database report. *Hered Cancer Clin Pract*. 2019 Feb 28;17:8. doi: 10.1186/s13053-019-0106-8. Impact Factor: 2,237

Weisner J, Landel I, Reintjes C, Uhlenbrock N, Trajkovic-Arsic M, Dienstbier N, Hardick J, Ladigan S, Lindemann M, Smith S, Quambusch L, Scheinpflug R, Depta L, Gontla R, Unger A, Müller H, Baumann M, Schultz-Fademrecht C, Günther G, Maghnouj A, Müller MP, **Pohl** M, Teschendorf C, Wolters H, Viebahn R, Tannapfel A, Uhl W, Hengstler JG, Hahn SA, Si-veke JT, Rauh D. Preclinical Efficacy of Covalent-Allosteric AKT Inhibitor Borussertib in Combination with Trametinib in *KRAS*-Mutant Pancreatic and Colorectal Cancer. *Cancer Res*. 2019 May 1;79(9):2367-2378. doi: 10.1158/0008-5472.CAN-18-2861. Impact Factor: 9,727

Beier D, Proescholt M, Reinert C, Pietsch T, Jones DTW, Pfister SM, Hattingen E, Seidel C, Dirven L, Luerding R, Reijneveld J, Warmuth-Metz M, Bonsanto M, Bremer M, Combs S, Rieken S, Herrlinger U, Kuntze H, Mayer-Steinacker R, Moskopp D, Schneider T, Beringer A, **Schlegel U**, Stummer W, Welker H, Weyerbrock A, Paulsen F, Rutkowski S, Weller M, Wick W, Kortman RD, Bogdahn U, Hau P. Multicenter pilot study of radio-chemotherapy as first-line treatment for adults with medullablastoma (NOA-07). *Neuro Oncol*. 2018;20: 400 - 410

Schäfer N, Proescholdt M, Steinbach JP, Weyerbrock A, Hau P, Grauer O, Goldbrunner R, Friedrich F, Rohde V, Ringel F, **Schlegel U**, Sabel M, Ronellenfitsch MW, Uhl M, Grau S, Hänel M, Schnell O, Krex D, Vajkoczy P, Tabatabai G, Mack F, Schaub C, Tzaridis T, Nießen M, Kebir S, Leutgeb B, Urbach H, Belka C, Stummer W, Glas M, Herrlinger U. Quality of life in the GLARIUS trial randomizing bevacizumab/irinotecan versus temozolomide in newly diagnosed, MGMT-nonmethylated glioblastoma. *Neuro Oncol* 2018;20: 975 - 985

Schlegel U, Korfel A. Is whole-brain radiotherapy still a standard treatment for primary central nervous system lymphomas? *Curr Opin Neurol*. 2018;31: 733 - 739

Von Baumgarten L, Illerhaus G, Korfel A, **Schlegel U**, Deckert M, Dreyling M. The diagnosis and treatment of Primary CNS Lymphoma. *Dtsch. Ärzteblatt* 2018;115: 419 - 426

Schaub C, Kebir S, Junold N, Hattingen E, Schäfer N, Steinbach JP, Weyerbrock A, Hau P, Goldbrunner R, Niessen M, Mack F, Stuplich M, Tzaridis T, Bähr O, Kortmann RD, **Schlegel U**, Schmidt-Graf F, Rohde V, Braun C, Hänel M, Sabel M, Gerlach R, Krex d, Belka C, Vatter H, Proescholdt M, Herrlinger U, Glas M. Tumor growth patterns of MGMT-non-methylated glioblastoma in the randomized GLARIUS trial. *J Cancer Clin Oncol*. 2018;144: 1581 - 1589

Baraniskin A, Chomiak M, Ahle G, Gress T, Buchholz M, Turewicz M, Eisenacher M, Margold M, **Schlegel U**, **Schmieg** W, Hahn S, **Schroers R**. Micro-RNA-30c as a novel diagnostic

biomarker for primary and secondary B-cell lymphoma of the CNS. *J Neurooncol.* 2018;137: 463 – 468

Althoff P, **Schmiegel** W, Lang G, Nicolas V, Brechmann T.
Creeping Fat Assessed by Small Bowel MRI Is Linked to Bowel Damage and Abdominal Surgery in Crohn's Disease.

Dig Dis Sci. 2018 Oct 1. doi: 10.1007/s10620-018-5303-1. [Epub ahead of print]

Impact Factor: 2,550

Affiliation BGH

Baraniskin A, Chomiak M, Ahle G, Gress T, Buchholz M, Turewicz M, Eisenacher M, Margold M, Schlegel U, **Schmiegel** W, Hahn S, **Schroers** R.

MicroRNA-30c as a novel diagnostic biomarker for primary and secondary B-cell lymphoma of the CNS.

J Neurooncol. 2018 Jan 11. doi: 10.1007/s11060-018-2749-0. [Epub ahead of print]

Impact Factor: 3,060

Engel C, Vasen HF, Seppälä T, Aretz S, Bigirwamungu-Bargeman M, de Boer SY, Bucksch K, Büttner R, Feder EH, Holzapfel S, Hüneburg R, Jacobs MAJM, Järvinen H, Kloor M, von Knebel Doeberitz M, Koornstra JJ, van Kouwen M, Langers AM, van de Meeberg PC, Morak M, Möslin G, Nagengast FM, Pylvanainen K, Rahner N, Renkonen-Sinisalo L, Sanduleanu S, Schackert HK, **Schmiegel** W, Schulmann K, Steinke-Lange V, Strassburg CP, Vecht J, Verhulst ML, de Vos Tot Nederveen Cappel W, Zachariae S, Mecklin JP, Loeffler M; German HNPCC Consortium, the Dutch Lynch Syndrome Collaborative Group, and the Finnish Lynch Syndrome Registry.

No Difference in Colorectal Cancer Incidence or Stage at Detection by Colonoscopy Among 3 Countries With Different Lynch Syndrome Surveillance Policies.

Gastroenterology. 2018 Jul 29. pii: S0016-5085(18)34818-2. doi: 10.1053/j.gastro.2018.07.030. [Epub ahead of print]

Impact Factor: 16,716

Kayser K, Degenhardt F, Holzapfel S, Horpaopan S, Peters S, Spier I, Morak M, **Vangala** D, Rahner N, von Knebel-Doeberitz M, Schackert HK, Engel C, Büttner R, Wijnen J, Doerks T, Bork P, Moebus S, Herms S, Fischer S, Hoffmann P, Aretz S, Steinke-Lange V.

Copy number variation analysis and targeted NGS in 77 families with suspected Lynch syndrome reveals novel potential causative genes.

Int J Cancer. 2018 Dec 1;143(11):2800-2813. doi: 10.1002/ijc.31725.

Impact Factor: 5,145

Klein-Scory S, Maslova M, **Pohl** M, Eilert-Micus C, **Schroers** R, **Schmiegel** W, **Baraniskin** A.

Significance of Liquid Biopsy for Monitoring and Therapy Decision of Colorectal Cancer.

Transl Oncol. 2018 Jan 19;11(2):213-220. doi: 10.1016/j.tranon.2017.12.010. [Epub ahead of print]

Impact Factor: 3,071

Rösch T, Altenhofen L, Kretschmann J, Hagen B, Brenner H, Pox C, **Schmiegel** W, Theilmeier A, Aschenbeck J, Tannapfel A, von Stillfried D, Zimmermann-Fraedrich K, Wegscheider K.

Risk of Malignancy in Adenomas Detected During Screening Colonoscopy.

Clin Gastroenterol Hepatol. 2018 Jun 11. pii: S1542-3565(18)30596-2. doi: 10.1016/j.cgh.2018.05.043. [Epub ahead of print]

Impact Factor: 7,896

Vogl TJ, Pereira PL, Helmberger T, Schreyer AG, **Schmiegel** W, Fischer S, Herzog C.

[Updated S3 Guidelines - Diagnosis and Treatment of Colorectal Carcinoma: Relevance for Radiological Diagnosis and Intervention].

Rofo. 2018 Sep 26. doi: 10.1055/a-0750-1762. [Epub ahead of print] German. No abstract available.

Kein Impact Factor

Vogl TJ, Pereira PL, Schreyer AG, **Schmiegel** W, Fischer S, Herzog C.

Updated S3 Guidelines - Diagnosis and Treatment of Colorectal Carcinoma: Relevance for Radiological Diagnosis and Intervention.

Rofo. 2018 Sep 24. doi: 10.1055/a-0721-1947. [Epub ahead of print] English, German.

Kein Impact Factor

Vangala DB, Cauchin E, Balmaña J, Wyrwicz L, van Cutsem E, Güller U, Castells A, Carneiro F, Hammel P, Ducreux M, van Laethem JL, Matysiak-Budnik T, **Schmiegel** W.

Screening and surveillance in hereditary gastrointestinal cancers: Recommendations from the European Society of Digestive Oncology (ESDO) expert discussion at the 20th European Society for Medical Oncology (ESMO)/World Congress on Gastrointestinal Cancer, Barcelona, June 2018. European Journal of Cancer, 2018 November;104:91-103.

<https://doi.org/10.1016/j.ejca.2018.09.004>

Impact Factor: 7,275